Timothy J. Scannell joined our Board in August of 2022.  He is currently an executive advisor at Stryker Corporation, a position he has held since retiring from his role as President and Chief Operating Officer in September 2021. Mr. Scannell served as President and Chief Operating Officer of Stryker from 2018 to 2021. Prior to this position, he served as group president, responsible for the MedSurg and Neurotechnology businesses at Stryker from 2008-2018. Prior to the group president role, Mr. Scannell served as vice president/general manager of Stryker Biotech and president of Stryker Spine.

Mr. Scannell is a director of publicly held Novocure, Insulet, Renalytix, and AeroClean Technologies.  Additionally, he is a director of privately held Collagen Matrix and Cerebral Therapeutics in addition to Synaptive.

Mr. Scannell holds a Bachelor of Business Administration and a Master of Business Administration from the University of Notre Dame.